Ascendis Pharma A/S Sponsored ADR Forecast, price target & analysts
Ascendis Pharma A/S Sponsored ADR Target price 2025 - Analyst rating & recommendation
Ascendis Pharma A/S Sponsored ADR Classifications & Recommendation:
Ascendis Pharma A/S Sponsored ADR Price Target
| Target Price | $252.96 |
| Price | $198.46 |
| Potential |
27.46%
register free of charge
|
| Number of Estimates | 19 |
|
19 Analysts have issued a price target Ascendis Pharma A/S Sponsored ADR 2026 .
The average Ascendis Pharma A/S Sponsored ADR target price is $252.96.
This is
27.46%
register free of charge
$322.35
62.43%
register free of charge
$205.03
3.31%
register free of charge
|
|
| A rating was issued by 23 analysts: 22 Analysts recommend Ascendis Pharma A/S Sponsored ADR to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ascendis Pharma A/S Sponsored ADR stock has an average upside potential 2026 of
27.46%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 425.49 | 856.78 |
| 36.34% | 101.36% | |
| EBITDA Margin | -72.67% | -24.88% |
| 55.06% | 65.76% | |
| Net Margin | -103.97% | -27.87% |
| 42.40% | 73.19% |
18 Analysts have issued a sales forecast Ascendis Pharma A/S Sponsored ADR 2025 . The average Ascendis Pharma A/S Sponsored ADR sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Ascendis Pharma A/S Sponsored ADR EBITDA forecast 2025. The average Ascendis Pharma A/S Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Ascendis Pharma A/S Sponsored ADR Analysts have issued a net profit forecast 2025. The average Ascendis Pharma A/S Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -7.64 | -3.91 |
| 23.68% | 48.82% | |
| P/E | negative | |
| EV/Sales | 14.75 |
18 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast for earnings per share. The average Ascendis Pharma A/S Sponsored ADR EPS is
This results in the following potential growth metrics and future valuations:
Ascendis Pharma A/S Sponsored ADR...
Current Ascendis Pharma A/S Sponsored ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B of A Securities |
Locked
➜
Locked
|
Locked | Sep 02 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B of A Securities:
Locked
➜
Locked
|
Sep 02 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 19 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 08 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
